SGA

iGRO™ supports individualised GH treatment for short children born small for gestational age (SGA) as soon as treatment starts.
It is a web-based medical device designed to be used in clinical practice — to predict how much a child may grow in the first and subsequent years of GH therapy.

It can be used to calculate growth predictions for children with Turner syndrome (TS) and provides evidence-based guidance and justification for GH treatment decisions.

It can be used to calculate growth predictions for short children born small for gestational age (SGA) and provides evidence-based guidance and justification for GH treatment decisions.

iGRO™ prediction algorithms can explain 30-52%1 of variability in growth responses to GH treatment for short children born SGA.

iGRO™ requires standard data that is routinely collected during clinic visits:

  • Birth date
  • Gender
  • Primary diagnosis
  • Birth weight
  • Parents’ heights
  • Height
  • Weight
  • Treatment start date
  • GH dose

 

 

1- Ranke, Michael B., et al. "Prediction of response to growth hormone treatment in short children born small for gestational age: analysis of data from KIGS (Pharmacia International Growth Database)." The Journal of Clinical Endocrinology & Metabolism 88.1 (2003): 125-131.